Literature DB >> 27112799

High prostate cancer gene 3 (PCA3) scores are associated with elevated Prostate Imaging Reporting and Data System (PI-RADS) grade and biopsy Gleason score, at magnetic resonance imaging/ultrasonography fusion software-based targeted prostate biopsy after a previous negative standard biopsy.

Stefano De Luca1, Roberto Passera2, Giovanni Cattaneo3, Matteo Manfredi3, Fabrizio Mele3, Cristian Fiori3, Enrico Bollito4, Stefano Cirillo5, Francesco Porpiglia3.   

Abstract

OBJECTIVE: To determine the association among prostate cancer gene 3 (PCA3) score, Prostate Imaging Reporting and Data System (PI-RADS) grade and Gleason score, in a cohort of patients with elevated prostate-specific antigen (PSA), undergoing magnetic resonance imaging/ultrasonography fusion software-based targeted prostate biopsy (TBx) after a previous negative randomised 'standard' biopsy (SBx). PATIENTS AND METHODS: In all, 282 patients who underwent TBx after previous negative SBx and a PCA3 urine assay, were enrolled. The associations between PCA3 score/PI-RADS and PCA3 score/Gleason score were investigated by K-means clustering, a receiver operating characteristic analysis and binary logistic regression.
RESULTS: The PCA3 score difference for the negative vs positive TBx cohorts was highly statistically significant. A 1-unit increase in the PCA3 score was associated to a 2.4% increased risk of having a positive TBx result. A PCA3 score of >80 and a PI-RADS grade of ≥4 were independent predictors of a positive TBx. The association between the PCA3 score and PI-RADS grade was statistically significant (the median PCA3 score for PI-RADS grade groups 3, 4, and 5 was 58, 104, and 146, respectively; P = 0.006). A similar pattern was detected for the relationship between the PCA3 score and Gleason score; an increasing PCA3 score was associated with a worsening Gleason score (median PCA3 score equal to 62, 105, 132, 153, 203, and 322 for Gleason Score 3+4, 4+3, 4+4, 4+5, 5+4, and 5+5, respectively; P < 0.001).
CONCLUSION: TBx improved PCA3 score diagnostic and prognostic performance for prostate cancer. The PCA3 score was directly associated both with biopsy Gleason score and PI-RADS grade: notably, in the 'indeterminate' PI-RADS grade 3 subgroup.
© 2016 The Authors BJU International © 2016 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  magnetic resonance imaging; prostate cancer; prostate cancer antigen 3 gene; targeted prostate biopsy

Mesh:

Substances:

Year:  2016        PMID: 27112799     DOI: 10.1111/bju.13504

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  5 in total

1.  Radiomic features on MRI enable risk categorization of prostate cancer patients on active surveillance: Preliminary findings.

Authors:  Ahmad Algohary; Satish Viswanath; Rakesh Shiradkar; Soumya Ghose; Shivani Pahwa; Daniel Moses; Ivan Jambor; Ronald Shnier; Maret Böhm; Anne-Maree Haynes; Phillip Brenner; Warick Delprado; James Thompson; Marley Pulbrock; Andrei S Purysko; Sadhna Verma; Lee Ponsky; Phillip Stricker; Anant Madabhushi
Journal:  J Magn Reson Imaging       Date:  2018-02-22       Impact factor: 4.813

2.  Diagnostic significance of urinary long non-coding PCA3 RNA in prostate cancer.

Authors:  Tao Wang; Xiangyun Qu; Jiajia Jiang; Peng Gao; Dingding Zhao; Xueqi Lian; Xiaohua Li
Journal:  Oncotarget       Date:  2017-04-20

3.  Clinical Significance of Peripheral Blood PCA3 Gene Expression in Early Diagnosis of Prostate Cancer.

Authors:  Lin Chunhua; Haiwei Zhao; Huishan Zhao; Youyi Lu; Jitao Wu; Zhenli Gao; Guojun Li; Yulian Zhang; Ke Wang
Journal:  Transl Oncol       Date:  2018-03-22       Impact factor: 4.243

Review 4.  Magnetic resonance imaging detection of prostate cancer in men with previous negative prostate biopsy.

Authors:  Matthew Truong; Thomas P Frye
Journal:  Transl Androl Urol       Date:  2017-06

Review 5.  Genetic Landscape of Prostate Cancer Conspicuity on Multiparametric Magnetic Resonance Imaging: A Systematic Review and Bioinformatic Analysis.

Authors:  Joseph M Norris; Benjamin S Simpson; Marina A Parry; Clare Allen; Rhys Ball; Alex Freeman; Daniel Kelly; Hyung L Kim; Alex Kirkham; Sungyong You; Veeru Kasivisvanathan; Hayley C Whitaker; Mark Emberton
Journal:  Eur Urol Open Sci       Date:  2020-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.